Seqens Seqens

X

Find US Patent Information with US Patent Number, Application Number and Patent Expiration Date of MolPort-000-883-877 on PharmaCompass.com

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

US DMFs Filed

US DMFs Filed

CEP/COS Certifications

CEP/COS Certifications

JDMFs Filed

JDMFs Filed

0

Other Certificates

Other Certificates

Other Suppliers

Other Suppliers

API REF. PRICE (USD / KG)
688
INTERMEDIATES
DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

Europe

Europe

Canada

Canada

Australia

Australia

South Africa

South Africa

Uploaded Dossiers

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

0

EXCIPIENTS
PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

USP

JP

0

Other Listed Suppliers

SERVICES
left grey arrow
right gray arrow
  • TABLET;ORAL - 12.5MG;75MG;50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
  • TABLET, EXTENDED RELEASE;ORAL - EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
  • CAPSULE;ORAL - 100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
  • TABLET;ORAL - 100MG;25MG
  • TABLET;ORAL - 200MG;50MG
  • TABLET;ORAL - 100MG
Flag U.S.A
Digital Content Digital Content
URL Supplier Web Content
8686026
Y
2031-06-09
207931
1
Abbvie Company Banner

Cophex 2024

Not Confirmed

envelop Contact Supplier
Flag U.S.A
Digital Content Digital Content
URL Supplier Web Content
8420596*PED
2031-10-10
207931
1
Abbvie Company Banner

Cophex 2024

Not Confirmed

envelop Contact Supplier
Flag U.S.A
Digital Content Digital Content
URL Supplier Web Content
9006387
2030-06-10
U-1687
207931
TREATMENT OF HCV INFECTION USING OMBITASVIR
1
Abbvie Company Banner

Cophex 2024

Not Confirmed

envelop Contact Supplier
Flag U.S.A
Digital Content Digital Content
URL Supplier Web Content
8268349*PED
2025-02-25
207931
1
Abbvie Company Banner

Cophex 2024

Not Confirmed

envelop Contact Supplier
Flag U.S.A
Digital Content Digital Content
URL Supplier Web Content
8686026
Y
2031-06-09
208624
1
Abbvie Company Banner

Cophex 2024

Not Confirmed

envelop Contact Supplier
Flag U.S.A
Digital Content Digital Content
URL Supplier Web Content
9044480
2031-04-10
U-1638
207931
TREATMENT OF HCV INFECTION USING PARITAPREVIR
1
Abbvie Company Banner

Cophex 2024

Not Confirmed

envelop Contact Supplier
Flag U.S.A
Digital Content Digital Content
URL Supplier Web Content
8399015
Y
2024-08-25
207931
1
Abbvie Company Banner

Cophex 2024

Not Confirmed

envelop Contact Supplier
Flag U.S.A
Digital Content Digital Content
URL Supplier Web Content
10105365
Y
2035-01-02
U-1889
208624
1
Abbvie Company Banner

Cophex 2024

Not Confirmed

envelop Contact Supplier
Flag U.S.A
Digital Content Digital Content
URL Supplier Web Content
8492386
2032-09-04
U-1840
208624
TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR, WITHOUT RIBAVIRIN
1
Abbvie Company Banner

Cophex 2024

Not Confirmed

envelop Contact Supplier
Flag U.S.A
Digital Content Digital Content
URL Supplier Web Content
8642538
Y
Y
2029-09-10
U-1638
207931
TREATMENT OF HCV INFECTION USING PARITAPREVIR
1
Abbvie Company Banner

Cophex 2024

Not Confirmed

envelop Contact Supplier
Flag U.S.A
Digital Content Digital Content
URL Supplier Web Content
8420596
Y
Y
2031-04-10
208624
1
Abbvie Company Banner

Cophex 2024

Not Confirmed

envelop Contact Supplier
Flag U.S.A
Digital Content Digital Content
URL Supplier Web Content
8188104
Y
Y
2029-05-17
U-1636
208624
USE OF DASABUVIR TO INHIBIT VIRAL REPLICATION FOR THE TREATMENT OF HCV INFECTION.
1
Abbvie Company Banner

Cophex 2024

Not Confirmed

envelop Contact Supplier
Flag U.S.A
Digital Content Digital Content
URL Supplier Web Content
8501238
Y
Y
2028-09-17
U-1636
208624
USE OF DASABUVIR TO INHIBIT VIRAL REPLICATION FOR THE TREATMENT OF HCV INFECTION.
1
Abbvie Company Banner

Cophex 2024

Not Confirmed

envelop Contact Supplier
Flag U.S.A
Digital Content Digital Content
URL Supplier Web Content
8691938
Y
Y
2032-04-13
208624
1
Abbvie Company Banner

Cophex 2024

Not Confirmed

envelop Contact Supplier
Flag U.S.A
Digital Content Digital Content
URL Supplier Web Content
9744170
Y
2035-01-02
U-1889
208624
1
Abbvie Company Banner

Cophex 2024

Not Confirmed

envelop Contact Supplier
Flag U.S.A
Digital Content Digital Content
URL Supplier Web Content
9006387
2030-06-10
U-1687
208624
TREATMENT OF HCV INFECTION USING OMBITASVIR
1
Abbvie Company Banner

Cophex 2024

Not Confirmed

envelop Contact Supplier
Flag U.S.A
Digital Content Digital Content
URL Supplier Web Content
10201541
Y
2032-05-17
208624
1
Abbvie Company Banner

Cophex 2024

Not Confirmed

envelop Contact Supplier
Flag U.S.A
Digital Content Digital Content
URL Supplier Web Content
8466159
2032-09-04
U-1637
208624
TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR WITH RIBAVIRIN.
1
Abbvie Company Banner

Cophex 2024

Not Confirmed

envelop Contact Supplier
Flag U.S.A
Digital Content Digital Content
URL Supplier Web Content
8399015
Y
2024-08-25
208624
1
Abbvie Company Banner

Cophex 2024

Not Confirmed

envelop Contact Supplier
Flag U.S.A
Digital Content Digital Content
URL Supplier Web Content
8680106
2032-09-04
U-1637
208624
TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR WITH RIBAVIRIN.
1
Abbvie Company Banner

Cophex 2024

Not Confirmed

envelop Contact Supplier
Flag U.S.A
Digital Content Digital Content
URL Supplier Web Content
9044480
2031-04-10
U-1638
208624
TREATMENT OF HCV INFECTION USING PARITAPREVIR
1
Abbvie Company Banner

Cophex 2024

Not Confirmed

envelop Contact Supplier
Flag U.S.A
Digital Content Digital Content
URL Supplier Web Content
8268349
Y
2024-08-25
207931
1
Abbvie Company Banner

Cophex 2024

Not Confirmed

envelop Contact Supplier
Flag U.S.A
Digital Content Digital Content
URL Supplier Web Content
10201584
2032-05-17
U-1889
208624
1
Abbvie Company Banner

Cophex 2024

Not Confirmed

envelop Contact Supplier
Flag U.S.A
Digital Content Digital Content
URL Supplier Web Content
9139536
2028-11-09
U-1753
208624
TREATMENT OF HCV INFECTION USING DISABUVIR
1
Abbvie Company Banner

Cophex 2024

Not Confirmed

envelop Contact Supplier
Flag U.S.A
Digital Content Digital Content
URL Supplier Web Content
8420596
Y
Y
2031-04-10
207931
1
Abbvie Company Banner

Cophex 2024

Not Confirmed

envelop Contact Supplier
Flag U.S.A
Digital Content Digital Content
URL Supplier Web Content
8685984
2032-09-04
U-1840
208624
TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR, WITHOUT RIBAVIRIN
1
Abbvie Company Banner

Cophex 2024

Not Confirmed

envelop Contact Supplier
Flag U.S.A
Digital Content Digital Content
URL Supplier Web Content
8691938
Y
Y
2032-04-13
207931
1
Abbvie Company Banner

Cophex 2024

Not Confirmed

envelop Contact Supplier
Flag U.S.A
Digital Content Digital Content
URL Supplier Web Content
8642538
Y
Y
2029-09-10
U-1638
208624
TREATMENT OF HCV INFECTION USING PARITAPREVIR
1
Abbvie Company Banner

Cophex 2024

Not Confirmed

envelop Contact Supplier
Flag U.S.A
Digital Content Digital Content
URL Supplier Web Content
8399015*PED
2025-02-25
207931
1
Abbvie Company Banner

Cophex 2024

Not Confirmed

envelop Contact Supplier
Flag U.S.A
Digital Content Digital Content
URL Supplier Web Content
8268349
Y
2024-08-25
208624
1
Abbvie Company Banner

Cophex 2024

Not Confirmed

envelop Contact Supplier
Flag U.S.A
Digital Content Digital Content
URL Supplier Web Content
9333204
Y
2035-01-02
U-1889
208624
1
Abbvie Company Banner

Cophex 2024

Not Confirmed

envelop Contact Supplier
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY